Newsfeeds Archive - Page 4 of 4

2 minute read

Theseus Pharmaceuticals Initial Dose Escalation Results From Ongoing Phase 1/2 Trial Of THE-630 Accepted For Online Publication At 2023 ASCO Annual Meeting

April 26, 10:07 AM

-- Company to host virtual investor event to review updated data on May 25, 2023 at 5:30pm ET -- CAMBRIDGE, Mass., April 26, 2023 /PRNewswire/ -- Theseus Pharmaceuticals, Inc. (NASDAQ:THRX)

THRX

1 minute read

Stifel Is Bullish On This ‘Competitive Late-Comer’ In Gastric Cancer Space

By Vandana Singh

March 16, 1:47 PM

Stifel has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a $24 price target. The company’s Predictive Resistance…

DCPH

4 minute read

Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

January 17, 2:21 PM

Gainers Celyad Oncology SA (NASDAQ: CYAD) jumped 187% to $2.30 after gaining 21% on Friday. Celyad Oncology, last month, decided to discontinue the development of its remaining clinical program CYAD-211.

ACER

1 minute read

Analyst Bullish On Theseus Pharma’s Platform For Gastric Cancer Therapies

By Vandana Singh

December 14, 2:20 PM

Needham has initiated coverage on Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22. Theseus’ discovery platform…

DCPH

6 minute read

Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

By Lisa Levin

November 14, 3:35 AM

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

1 minute read

Earnings

Recap: Theseus Pharmaceuticals Q3 Earnings

By Benzinga Insights

November 3, 9:25 AM

Theseus Pharmaceuticals (NASDAQ:THRX) reported its Q3 earnings results on Thursday, November 3, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

THRX

1 minute read

Theseus Pharmaceuticals Nominates THE-349, A Fourth-Generation EGFR Inhibitor Development Candidate In Non-Small Cell Lung Cancer

By Benzinga Newsdesk

October 3, 7:04 AM

THE-349 is a fourth-generation, potent and selective, small molecule designed to inhibit all major classes of EGFR activating and resistance mutations Preclinical data to be presented at the 34th EORTC-NCI-AACR

THRX

1 minute read

Theseus Pharmaceuticals Q2 EPS $(0.30) Up From $(6.82) YoY

By Benzinga Newsdesk

August 11, 7:34 AM

Theseus Pharmaceuticals (NASDAQ:THRX) reported quarterly losses of $(0.30) per share. This is a 95.6 percent increase over losses of $(6.82) per share from the same period last year.

THRX

1 minute read

HC Wainwright Sees Over 300% Upside In This Cancer-Focused Stock

By Vandana Singh

July 1, 12:48 PM

HC Wainwright has initiated Theseus Pharmaceuticals Inc (NASDAQ:THRX) with a Buy rating and a price target of $22 (310% upside). The analysts see…

THRX